|Table of Contents|

Comparison of efficacy and safety between cisplatin-based and carboplatin-based chemotherapy in the treatment of children with extracranial malignant germ cell tumor

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 22
Page:
4212-4216
Research Field:
Publishing date:

Info

Title:
Comparison of efficacy and safety between cisplatin-based and carboplatin-based chemotherapy in the treatment of children with extracranial malignant germ cell tumor
Author(s):
JIAO Yangyang; FU Pan; YANG Jingwei; JIANG Shayi; LIAO Xuelian; SHAO Jingbo
Department of Hematology and Oncology,Shanghai Children's Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200062,China.
Keywords:
extracranial MGCT; chemotherapy regimen; comparative analysis; adverse reaction
PACS:
R737
DOI:
10.3969/j.issn.1672-4992.2023.22.021
Abstract:
Objective:To analyze the efficacy and adverse reaction of children with extracranial malignant germ cell tumor (MGCT) treated with either cisplatin-based or carboplatin-based chemotherapy.Methods:We reviewed clinical data of children with extracranial MGCT initially treated in department of hematology and oncology of our hospital from January 2014 to December 2020.The general data,2-year overall survival (OS),2-year event-free survival (EFS),relapse rate,the incidence of pulmonary infection,hepatic toxicity,renal toxicity and cardiac toxicity,duration of chemotherapy,number of myelosuppression after chemotherapy,and length of hospital stay were compared between the two groups.Results:In 67 patients,45 cases were treated with cisplatin-based chemotherapy (cisplatin group) and 22 cases were treated with carboplatin-based chemotherapy (carboplatin group).The median follow-up time was 60 months (range from 31 to 85 months) in cisplatin group and 19.5 months (range from 8 to 41 months) in carboplatin group.In cisplatin group and carboplatin group,two-year OS was 100% and 95.5% (P=0.278),two-year EFS with 95.6% and 90.4% (P=0.527),the relapse rate with 6.7% and 9.1% (P=0.534).The incidence of pneumonia was 57.8% and 27.3% (P=0.019).There was no significant difference in the incidence of myelosuppression,hepatotoxicity,nephrotoxicity,cardiotoxicity and treatment course.Hospitalization rate ralated to myelosuppression with infection after chemotherapy was 23.3% and 12.7% (P=0.013) respectively,but there was no significant difference in hospital stays.No significant difference was observed in relapse rate and grade IV myelosuppression rate after chemotherapy between different risk groups.Conclusion:While obtaining a positive effect of extracranial MGCT in children,carboplatin-based chemotherapy can reduce the probability of pneumonia and hospitalization rate of infection due to myelosuppression after chemotherapy.

References:

[1] HULSKER CCC,EL MANSORI I,FIOCCO M,et al.Treatment and survival of malignant extracranial germ cell tumours in the paediatric population:a systematic review and meta-analysis［J］.Cancers (Basel),2021,13(14):3561.
[2] FRAZIER AL,HALE JP,RODRIGUEZ-GALINDO C,et al.Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States［J］.J Clin Oncol,2015,33(2):195-201.
[3] DEPANI S,STONEHAM S,KRAILO M,et al.Results from the UK Children's Cancer and Leukaemia Group study of extracranial germ cell tumours in children and adolescents (GCIII)［J］.Eur J Cancer,2019,118:49-57.
[4] D'ANGELO P,DE PASQUALE MD,BARRETTA F,et al.Malignant sacrococcygeal germ cell tumors in childhood:The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience［J］.Pediatr Blood Cancer,2021,68(3):e28812.
[5] FAURE-CONTER C,ORBACH D,SUDOUR-BONNANGE H,et al.Extracranial germ cell tumours in children and adolescents:Results from the French TGM13 protocol［J］.Pediatr Blood Cancer,2023,70(3):e30117.
[6] GHEORGHE-CETEAN S,CAINAP C,OPREAN L,et al.Platinum derivatives:a multidisciplinary approach［J］.J BUON,2017,22(3):568-577.
[7] KNIGHT KR,CHEN L,FREYER D,et al.Group-wide,prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy (ACCL05C1):A report from the Children's Oncology Group［J］.J Clin Oncol,2017,35(4):440-445.
[8] WEIL BR,BILLMIRE DF.Management of germ cell tumors in pediatric patients［J］.Surg Oncol Clin N Am,2021,30(2):325-338.
[9] SHAIKH F,CULLEN JW,OLSON TA,et al.Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors:a report from the Children's Oncology Group［J］.J Clin Oncol,2017,35(11):1203-1210.
[10] FUNG C,SESSO HD,WILLIAMS AM,et al.Multi-institutional assessment of adverse health outcomes among north american testicular cancer survivors after modern cisplatin-based chemotherapy［J］.J Clin Oncol,2017,35(11):1211-1222.
[11] FRAZIER AL,STONEHAM S,RODRIGUEZ-GALINDO C,et al.Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours:A report of the Malignant Germ Cell International Consortium［J］.Eur J Cancer,2018,98:30-37.
[12] JAIN R,MENON P,BANSAL D,et al.Outcome of pediatric germ cell tumor with comparison of carboplatin and cisplatin based regimens:A 10-year analysis［J］.Pediatr Hematol Oncol,2022,39(3):267-277.
[13] BREGLIO AM,RUSHEEN AE,SHIDE ED,et al.Cisplatin is retained in the cochlea indefinitely following chemotherapy［J］.Nat Commun,2017,8(1):1654.
[14] DE PASQUALE MD,D'ANGELO P,CROCOLI A,et al.Salvage treatment for children with relapsed/refractory germ cell tumors:The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience［J］.Pediatr Blood Cancer,2020,67(3):e28125.
[15] PASHANKAR F,FRAZIER AL,KRAILO M,et al.Treatment of refractory germ cell tumors in children with paclitaxel,ifosfamide,and carboplatin:A report from the Children's Oncology Group AGCT0521 study［J］.Pediatr Blood Cancer,2018,65(8):e27111.
[16] RAMANATHAN S,PRASAD M,VORA T,et al.Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue:Experience from a tertiary cancer center［J］.Pediatr Blood Cancer,2023,70(4):e30179.
[17] FONSECA A,FRAZIER AL,SHAIKH F.Germ cell tumors in adolescents and young adults［J］.J Oncol Pract,2019,15(8):433-441.
[18] SHAIKH F,STARK D,FONSECA A,et al.Outcomes of adolescent males with extracranial metastatic germ cell tumors:A report from the Malignant Germ Cell Tumor International Consortium［J］.Cancer,2021,127(2):193-202.
[19] SUDOUR-BONNANGE H,FAURE-CONTER C,MARTELLI H,et al.Primary mediastinal and retroperitoneal malignant germ cell tumors in children and adolescents:Results of the TGM95 trial,a study of the French Society of Pediatric Oncology［J］.Pediatr Blood Cancer,2017,64(9):e26494.
[20] CHEN CH,WU KH,CHAO YH,et al.Clinical manifestation of pediatric mediastinal tumors,a single center experience［J］.Medicine (Baltimore),2019,98(32):e16732.
[21] WU P,YANG Y,YU Z,et al.Clinical features and survival outcomes in children and adolescents with malignant mediastinal germ cell tumors based on surveillance,epidemiology,and end results database analysis［J］.J Surg Res,2023,288:362-371.

Memo

Memo:
-
Last Update: 1900-01-01